Eli Lilly and Novo Nordisk Win Antitrust Lawsuit Dismissal; Replimune Melanoma Drug and Medicare Policy Changes in Focus

Source Summary

A federal judge dismissed an antitrust lawsuit against Eli Lilly and Novo Nordisk filed by a compound pharmacy. The news also covers Replimune's melanoma drug development and recent Medicare policy changes affecting the pharmaceutical industry.